Biogen Ma Inc.

Sunesis Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

Biogen Idec Ma Inc.

Lei Zhang

Kevin Guckian

Lihong Sun

Gnanasambandam Kumaravel

Zhili Xin

Bin Ma

Timothy Raymond Chan

Arthur G Taveras

Deping Wang

Sha Mi

Jeffrey Vessels

Zhaohui Shao

Edward Yin Shiang Lin

Nathan Genung

Ryan Gianatassio

Joseph P Lyssikatos

Kevin Koch

Brian T Hopkins

Wen-Cherng Lee

Edward Yin-Shiang Lin

Daniel A Erlanson

Hairuo Peng

Hua Miao

Daniel M Scott

Jermaine Thomas

Robert Lowell Simmons

Stig Hansen

Joseph Arndt

Kathy Jingyuan Cao

Kurt D Van Vloten

Bradley T Tangonan

Nuzhat Pathan

Kenneth Egnard Lind

Daniel Erlanson

Kevin M Guckian

Kurt Van Vloten

Described herein are compounds represented by formula (I) (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, and Z are as defined herein.

Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R, R, R, Y, Y, m, n, and p are as defined herein.

Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R, R, R, Y, Y, Ar, Z and n are as defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

Described herein are compounds represented by formula (I&#x2033;) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, R, R, m, n, Y, Y, Rand Rare defined herein.

O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors

Biaryl inhibitors of Bruton'S tyrosine kinase

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Compounds that are S1P modulating agents and/or ATX modulating agents

Biaryl inhibitors of bruton's tyrosine kinase

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Heterocyclic compounds useful as PDK1 inhibitors

Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.

ATX modulating agents

Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). 

The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

Methods of treatment using pyridinonyl PDK1 inhibitors

Compounds of formula (I) can modulate the activity of autotaxin (ATX).

Growing community of inventors

Westford, MA, United States of America

Lei Zhang